title: Platelet kinetics in dogs treated with a glycoprotein IIb/IIIa peptide antagonist.
abstract: Platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists have been highly effective inhibitors of platelet aggregation in preclinical studies and in clinical trials. However, decreased platelet counts have been documented in preclinical studies and in some patients receiving GPIIb/IIIa antagonists. We evaluated changes in platelet kinetics and fate in dogs receiving the GPIIb/IIIa receptor antagonist RPR 109891 orally for 4 days. Dogs receiving RPR 109891 had a 22-52% decrease in platelet count with the nadirs at 3-5 days after initiation of treatment. Platelet survival time was reduced by 19%, and platelet half-life was reduced by 63%. Indium-111-labeled platelets were rapidly cleared from the blood within 1 hour after administration of RPR 109891 on treatment days 1 and 2. This clearing was associated with a sharp increase in radioactivity in spleen but not in liver or lung. Platelet clearance was markedly attenuated on treatment days 3 and 4. Platelet counts returned to baseline within 1 week after discontinuation of treatment. These data indicate that RPR 109891 causes rapid and selective sequestration of platelets in the spleen.
authors.affiliation: Department of Veterinary PathoBiology, College of Veterinary Medicine, University of Minnesota, St. Paul 55108, USA. weiss005@tc.umn.edu
authors.forename: D J
authors.initials: DJ
authors.lastname: Weiss
authors.forename: M L
authors.initials: ML
authors.lastname: Mirsky
authors.forename: O A
authors.initials: OA
authors.lastname: Evanson
authors.forename: J
authors.initials: J
authors.lastname: Fagliari
authors.forename: D
authors.initials: D
authors.lastname: McClenahan
authors.forename: B
authors.initials: B
authors.lastname: McCullough
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D005260:Female; D006207:Half-Life; D007700:Kinetics; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011877:Radionuclide Imaging; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex